BridgeBio Corporation (BBIO) presented its genetic disease pipeline at the 12th Annual Cantor Fitzgerald Global Healthcare Conference in September 2026, emphasizing its four core programs—Attruby, BBP-418, infigratinib, and encaleret—as potential drivers of peak-year sales exceeding $8 billion. The company also highlighted an additional $2 billion opportunity from a hypoparathyroidism expansion program, with revenue growth of 202% in the prior year to $713 million and a projected 101% increase for fiscal 2026. Management expects Attruby alone to exceed $1 billion in annualized sales by mid-2024, with quarterly growth of $25 million to $30 million through 2027–2028.
Attruby, a second-generation transthyretin (TTR) stabilizer for ATTR cardiomyopathy (ATTR-CM), dominates BridgeBio’s strategy. The drug has captured over 25% of frontline U.S. patients, with penetration exceeding 50% in Germany. Its rapid onset—about one month compared to 18 months for knockdown therapies—positions it as the preferred frontline treatment, per Chinmay Shukla, Senior Vice President of Investor Relations. The company projects a $4 billion market opportunity for Attruby, with generic entry of the first-generation stabilizer, Vyndamax, expected no earlier than mid-2031, securing a four- to five-year exclusivity window.
BBP-418, a treatment for limb-girdle muscular dystrophy 2I/R9, targets an estimated 7,000 patients in the U.S. and Europe, with 2,000–2,500 in the U.S. The drug is dosed at 9 grams twice daily for patients weighing 30 kg and 12 grams for heavier patients, with a November 2024 PDUFA date. Infigratinib, the first oral treatment for achondroplasia, showed significant benefits in sleep apnea and ear infections in Phase 2 trials, with U.S. penetration at 30% versus 75% in Europe. Encaleret, for autosomal dominant hypocalcemia type 1 and chronic hypoparathyroidism, achieved 76% disease resolution in Phase 3 trials, prompting the FDA to designate it a priority review.
BridgeBio’s cash position stands at $1.7 billion as of July 2024, supporting its expansion. Competitors like VOXZOGO, Yuviwel, and SKYTROFA are noted, but Attruby’s rapid onset and established lead position in ATTR-CM remain its strongest asset. Analysts cite price targets ranging from $80 to $157 per share, with BridgeBio’s gross profit margin at 94% as it navigates a pipeline poised for substantial growth.
The company’s sister company, GondolaBio, is also active in the space, but BridgeBio’s focus remains on its core programs, with hypoparathyroidism trials expected to read out in late 2027 or 2028.
